| Literature DB >> 29573222 |
Tor Paaske Utheim1,2,3,4,5,6, Øygunn Aass Utheim7, Panagiotis Salvanos2, Catherine J Jackson1,5,6, Stefan Schrader8, Gerd Geerling8, Amer Sehic5.
Abstract
Limbal stem cell deficiency (LSCD) can result from a variety of corneal disorders, including chemical and thermal burns, infections, and autoimmune diseases. The symptoms of LSCD may include irritation, epiphora, blepharospasms, photophobia, pain, and decreased vision. There are a number of treatment options, ranging from nonsurgical treatments for mild LSCD to various forms of surgery that involve different cell types cultured on various substrates. Ex vivo expansion of limbal epithelial cells (LEC) involves the culture of LEC harvested either from the patient, a living relative, or a cadaver on a substrate in the laboratory. Following the transfer of the cultured cell sheet onto the cornea of patients suffering from LSCD, a successful outcome can be expected in approximately three out of four patients. The phenotype of the cultured cells has proven to be a key predictor of success. The choice of culture substrate is known to affect the phenotype. Several studies have shown that amniotic membrane (AM) can be used as a substrate for expansion of LEC for subsequent transplantation in the treatment of LSCD. There is currently a debate over whether AM should be denuded (i.e., de-epithelialized) prior to LEC culture, or whether this substrate should remain intact. In addition, crosslinking of the AM has been used to increase the thermal and mechanical stability, optical transparency, and resistance to collagenase digestion of AM. In the present review, we discuss the rationale for using altered versus unaltered AM as a culture substrate for LEC. Stem Cells Translational Medicine 2018;7:415-427.Entities:
Keywords: Cell biology; Cell transplantation; Cornea; Gene expression
Mesh:
Year: 2018 PMID: 29573222 PMCID: PMC5905228 DOI: 10.1002/sctm.17-0257
Source DB: PubMed Journal: Stem Cells Transl Med ISSN: 2157-6564 Impact factor: 6.940
Figure 1Schematic representation of the five‐layered human amniotic membrane.
Clinical studies using ex vivo expansion of LEC on intact amniotic membrane
| Author, year | Culture system | Air‐lifting | 3T3 | Immunosuppression | Follow‐up time (months) | Clinical success |
|---|---|---|---|---|---|---|
| Tsai et al. (2000) | Autologous explant | No | No | No | Mean: 15 (12–18) | Stable ocular surface: 100% |
| Visual acuity: Improved in 83% | ||||||
| Conjunctivalization: No | ||||||
| Grueterich et al. (2002) | Autologous explant | No | No | No | 21 | Stable ocular surface: 100% |
| Visual acuity: Improved | ||||||
| Conjunctivalization: No | ||||||
| Tseng et al. (2002) | Autologous and allogeneic explant | No | No | No | 14 | Stable ocular surface: 100% |
| Visual acuity: Improved in 83% | ||||||
| Conjunctivalization: No | ||||||
| Fatima et al. (2007) | Autologous explant | No | No | Topical steroids | 37 | Stable ocular surface: 100% |
| Visual acuity: Improved | ||||||
| Conjunctivalization: No | ||||||
| Kolli et al. (2010) | Autologous explant | No | No | Topical steroids | Mean: 19 (12–30) | Stable ocular surface: 100% |
| Visual acuity: Improved in 62% | ||||||
| Conjunctivalization: No | ||||||
| Pauklin et al. (2010) | Allogeneic explant | No | No | Cyclosporin A | Mean: 28.5 ± 14.9 | Stable ocular surface: 68% |
| Visual acuity: Improved in 73% | ||||||
| Conjunctivalization: No | ||||||
| Pathak et al. (2013) | Autologous explant | No | No | Topical steroids | 11–48 | Stable ocular surface: 56% |
| Visual acuity: Improved in 22% | ||||||
| Conjunctivalization: 440025; |
Abbreviation: LEC, limbal epithelial cells.
Clinical studies using ex vivo expansion of LEC on denuded amniotic membrane
| Author, year | Culture system | Air‐lifting | 3T3 | Immunosuppression | Follow‐up time (months) | Clinical success |
|---|---|---|---|---|---|---|
| Schwab et al. (2000) | Autologous and allogeneic cell suspension | Yes | Yes | Topical and systemic steroids, Cyclosporin A | Median: 11 (6–19) | Stable ocular surface: 71% |
| Visual acuity: Improved in 100% | ||||||
| Conjunctivalization: 29% | ||||||
| Koizumi et al. (2001) | Allogeneic explant | Yes | Yes | Systemic steroids, Cyclosporin A, Cyclophosphamide | Mean: 11.2 ± 1.3 | Stable ocular surface: 77% |
| Visual acuity: Improved in 100% | ||||||
| Conjunctivalization: 23% | ||||||
| Koizumi et al. (2001) | Allogeneic explant | Yes | Yes | Systemic steroids, Cyclosporin A, Cyclophosphamide | 6 | Stable ocular surface: 100% |
| Visual acuity: Improved in 100% | ||||||
| Conjunctivalization: No | ||||||
| Shimazaki et al. (2002) | Allogeneic explant | No | No | Topical and systemic steroids, Cyclosporin A | Short‐term | Stable ocular surface: 46% |
| Visual acuity: Improved in 77% | ||||||
| Conjunctivalization: 38% | ||||||
| Nakamura et al. (2003) | Allogeneic explant | Yes | Yes | Systemic steroids, Cyclosporin A, Cyclophosphamide | 14 | Stable ocular surface: 100% |
| Visual acuity: Markedly improved | ||||||
| Conjunctivalization: No | ||||||
| Sangwan et al. (2003) | Allogeneic explant | No | No | No | 5 | Stable ocular surface: 100% |
| Visual acuity: Improved in 100% | ||||||
| Conjunctivalization: No | ||||||
| Harkin et al. (2004) | Autologous cell suspension | Yes | Yes | No | 15 | Stable ocular surface: 100% |
| Visual acuity: Improved in 100% | ||||||
| Conjunctivalization: Not reported | ||||||
| Nakamura et al. (2004) | Autologous explant | Yes | Yes | Systemic steroids, Cyclosporin A, Cyclophosphamide | 19 | Stable ocular surface: 100% |
| Visual acuity: Improved in 100% | ||||||
| Conjunctivalization: No | ||||||
| Sangwan et al. (2005) | Autologous and allogeneic explant | No | No | Systemic steroids, Cyclosporin A | Mean: 8.3 ± 5.0 | Stable ocular surface: 93% |
| Visual acuity: Improved in 53% | ||||||
| Conjunctivalization: No | ||||||
| Sangwan et al. (2005) | Autologous and allogeneic explant | No | No | Systemic steroids, Cyclosporin A | 25–34 | Stable ocular surface: 100% |
| Visual acuity: Improved in 100% | ||||||
| Conjunctivalization: No | ||||||
| Fatima et al. (2006) | Autologous explant | No | No | No | 6 | Stable ocular surface: 100% |
| Visual acuity: Improved | ||||||
| Conjunctivalization: No | ||||||
| Nakamura et al. (2006) | Autologous and allogeneic cell suspension | Yes | Yes | Systemic steroids, Cyclosporin A, Cyclophosphamide | Mean: 14.6 ± 4.4 | Stable ocular surface: 100% |
| Visual acuity: Improved | ||||||
| Conjunctivalization: No | ||||||
| Sangwan et al. (2006) | Autologous explant | No | No | No | Mean: 18.3 | Stable ocular surface: 73% |
| Visual acuity: Improved | ||||||
| Conjunctivalization: No | ||||||
| Ang et al. (2007) | Allogeneic cell suspension | Yes | Yes | Systemic steroids, Cyclosporin A, Cyclophosphamide | 48 | Stable ocular surface: 100% |
| Visual acuity: Improved | ||||||
| Conjunctivalization: No | ||||||
| Kawashima et al. (2007) | Autologous and allogeneic explant | Yes | Yes | Systemic steroids, Cyclosporin A | Mean: 25.1 ± 13.2 | Stable ocular surface: 100% |
| Visual acuity: Improved | ||||||
| Conjunctivalization: No | ||||||
| Shimazaki et al. (2007) | Autologous cell suspension | No | No | Systemic steroids, Cyclosporin A | 31 | Stable ocular surface: 59% |
| Visual acuity: Improved | ||||||
| Conjunctivalization: No | ||||||
| Shortt et al. (2008) | Autologous and allogeneic cell suspension | No | No | Systemic steroids, Cyclosporin A | 13 | Stable ocular surface: 100% |
| Visual acuity: Improved in 70% | ||||||
| Conjunctivalization: No | ||||||
| Gomes et al. (2009) | Allogeneic explant | Yes | Yes | Systemic steroids | 12 | Stable ocular surface: 100% |
| Visual acuity: Improved | ||||||
| Conjunctivalization: Yes | ||||||
| Sahu et al. (2009) | Autologous explant | No | No | Topical steroids | 10 | Stable ocular surface: 100% |
| Visual acuity: Improved | ||||||
| Conjunctivalization: No | ||||||
| Satake et al. (2009) | Autologous explant | No | No | No | 43 | Stable ocular surface: 100% |
| Visual acuity: Improved | ||||||
| Conjunctivalization: No | ||||||
| Baradaran‐Rafii et al. (2010) | Autologous explant | No | No | Topical and systemic steroids | Mean: 34.0 ± 13.5 | Stable ocular surface: 100% |
| Visual acuity: Improved | ||||||
| Conjunctivalization: 12% | ||||||
| Dobrowolski et al. (2011) | Autologous explant | Yes | Yes | No | Mean: 4.9 ± 1.1 | Stable ocular surface: 72% |
| Visual acuity: Improved | ||||||
| Conjunctivalization: 60% | ||||||
| Sangwan et al. (2011) | Autologous explant | Yes | Yes | Systemic steroids | Mean: 36.0 ± 19.2 | Stable ocular surface: 71% |
| Visual acuity: Improved in 60% | ||||||
| Conjunctivalization: Yes | ||||||
| Sharma et al. (2011) | Autologous and allogeneic explant | No | No | Systemic steroids, Cyclosporin A | Mean: 11.0 ± 8.0 | Stable ocular surface: 68% |
| Visual acuity: Improved in 74% | ||||||
| Conjunctivalization: Yes | ||||||
| Basu et al. (2012) | Autologous explant | No | No | Topical steroids | Mean: 27.6 ± 16.8 | Stable ocular surface: 100% |
| Visual acuity: Improved in 76% | ||||||
| Conjunctivalization: 34% | ||||||
| Shigeyasu et al. (2012) | Autologous and allogeneic explant | Yes | Yes | Topical steroids | 48–66 | Stable ocular surface: 100% |
| Visual acuity: Improved | ||||||
| Conjunctivalization: No | ||||||
| Vazirani et al. (2014) | Autologous and allogeneic explant | No | No | Topical steroids | 12 | Stable ocular surface: 63% |
|
Visual acuity: Improved in 100% | ||||||
| Guarnieri et al. (2014) | Autologous explant | No | No | Topical steroids | Mean: 17.5 ± 7 | Stable ocular surface: 59% |
|
Visual acuity: Improved in 63% | ||||||
| Zakaria et al. (2014) | Autologous and allogeneic explant | No | No | Systemic steroids, Cyclosporin A | Mean: 22 (4–43) | Stable ocular surface: 67% |
| Visual acuity: Improved | ||||||
| Conjunctivalization: Yes |
Abbreviation: LEC, limbal epithelial cells.
Different methods and effects of crosslinking of amniotic membrane
| Author, year | Crosslinking type | Methods | Results |
|---|---|---|---|
| Fujisato et al. (1999) | GA and radiation crosslinked amniotic membrane | Measurement of water content, membrane permeability, and mechanical properties; In vitro degradation test of membranes | Radiation decreased the tensile strength; Protein permeation not influenced by the GA concentration; GA crosslinking increased the biodegradation properties of the membranes; Radiation crosslinking is less effective than GA crosslinking |
| Spoerl et al. (2004) | GA crosslinked amniotic membrane | Measurement of biomechanical force‐elongation and resistance to enzymatic digestion; Transplantation to patients with ocular surface defects | Significantly increased biomechanical strength of GA crosslinked membranes; Membranes were completely resistant to enzymatic digestion; The membranes did not dissolve for months after transplantation |
| Ma et al. (2010) | Carbodiimide (EDC/NHS) crosslinked amniotic membrane | ATR‐FTIR; DSC; EM; Mechanical degradation tests; Membrane permeability | The optimal concentration was 0.05 mmol EDC/mg amniotic membrane; Increased mechanical and thermal stability, optical transparency, and resistance to collagenase digestion; EDC/NHS crosslinked membranes supported LEC proliferation and preserved epithelial progenitor cells in vitro and in vivo |
| Kitagawa et al. (2011) | Hyperdried GA crosslinked amniotic membrane | Transplantation with hyperdried GA crosslinked amniotic membrane; In vitro degradation tests | Hyperdried GA crosslinked amniotic membrane did not dissolve until 48 hours; Corneal perforation repaired after transplantation; No recurrence during follow‐up period 3–6 months |
| Tanaka et al. (2012) | Carbodiimide crosslinked amniotic membrane | Measurement of light transmittance and tensile strength | Significantly increased tensile strength after crosslinking; Greater light transmittance in crosslinked membranes under wet conditions |
| Lai et al. (2013) | Carbodiimide crosslinked amniotic membrane | Varying crosslinking durations (1–4 hours); Measurement of light transmittance, water content; In vitro degradation tests | Increased water content, light transmittance, and resistance to enzymatic degradation; Enhanced LEC growth and increased expression of p63 and ABCG2 on membranes with greater crosslinking degree |
| Lai et al. (2013) | GA crosslinked amniotic membrane | In vitro degradation tests; Ninhydrin assays; TEM | Significant collagen molecular aggregation; Crosslinking with GA for 6 hours resulted in lowest in vitro degradability of the membranes |
| Sekar et al. (2013) | Al2(SO4)3 crosslinked amniotic membrane | Measurement of mechanical properties, percentage of swelling in water, and sterility; In vitro static culture system; Infrared spectroscopy; SEM | 125% increase in the tensile strength in the crosslinked membranes; Membrane was sterile up to 1 year; Confluent sheets of epithelial cell at the end of 14th day resembled the morphology of limbal epithelium |
| Lai (2014) | Photo‐crosslinked amniotic membrane | Measurement of crosslinking structure, degradability, and nutrient permeation ability; Expression of ABCG2 | The number of crosslinks per unit mass of membrane increased with increasing illumination; Biological stability and matrix permeability dependent of the crosslinking density; Increased expression of ABCG2; LEC exhibited the undifferentiated precursor cell phenotype |
| Lai et al. (2014) | L‐lysine Carbodiimide crosslinked amniotic membrane | Measurement of crosslinking structure, water content, light transmittance, and cell viability; In vitro degradation tests; Expression of p63 and ABCG2 | Increase in L‐lysine concentration increased crosslinking density and decreased water content; Decreased thermal denaturation and enzymatic degradation in accordance with the number of crosslinks; High levels of L‐lysine decreased light transmittance and biocompatibility; Increased expression of p63 and ABCG2 was dependent on improved crosslinking formation |
| Lai (2015) | Carbodiimide crosslinked amniotic membrane (treated with glycine, lysine, or glutamic acid) | Measurement of crosslinking structure, diffusion permeability, biocompatibility, and zeta potential; In vitro degradation tests | Addition of lysine to crosslinked membranes improved formation of covalent crosslinkages and increased tensile strength; Crosslinked membrane implants exhibited biocompatibility; Glycine molecules were insufficient to increase the resistance to thermal denaturation and enzymatic degradation |
| Ma et al. (2015) | Carbodiimide (EDC/NHS) crosslinked amniotic membrane | Culture of LEC; Colony formation efficiency; Immunoconfocal microscopy; Real‐time qRT‐PCR; Western blot | LEC cultured on EDC/NHS crosslinked membranes exhibited great colony formation efficiency and expressed high levels of p63, ABCG2, integrin B1, and integrin‐linked kinase; Membranes exhibited high rigidity and rough ultrastructure, and preserved progenitor LEC in vitro |
Abbreviations: ATR‐FTIR, attenuated total reflection‐Fourier transform infrared spectroscopy; EDC, 1‐ethyl‐3‐(3‐dimethyl aminopropyl) carbodiimide hydrochloride; DSC, differential scanning calorimetry; EM, electron microscopy; GA, glutaraldehyde; LEC, limbal epithelial cells; NHS, N‐hydroxysuccinimide; qRT‐PCR, quantitative real‐time polymerase chain reaction; SEM, scanning electron microscopy; TEM, transmission electron microscopy.